growth arrest specific 2 like 1 pseudogene 2Genealiases: []
Q-omics provides the consensus-scored GAS2L1P2 profile across patient tissues and cancer cell-line models. GAS2L1P2 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in CESC. Among the 18 cancer types available for tumor–normal comparison, GAS2L1P2 is differentially expressed in 9, with the highest sampling consensus in KIRP. Additionally, GAS2L1P2 RNA expression shows 11,694 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight CESC, KIRP, and TGCT as cancer lineages where GAS2L1P2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GAS2L1P2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GAS2L1P2 survival associations across molecular data types. GAS2L1P2 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GAS2L1P2 RNA expression–survival associations across cancer types. High GAS2L1P2 expression shows unfavorable associations in UVM, PRAD and DLBC, but favorable associations in CESC, SKCM and UCS. The CESC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify CESC as the clearest survival context for GAS2L1P2 RNA expression.
This table summarizes GAS2L1P2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for GAS2L1P2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GAS2L1P2 shows lower tumor expression in KIRP, KIRC, THCA, KICH and BLCA and higher tumor expression in HNSC. The KIRP box plot shows higher GAS2L1P2 RNA expression in normal versus tumor tissue (log2 FC = −0.906, t-test p < 0.001).
This table shows molecular features associated with GAS2L1P2 in patient tissues and cancer cell lines. In patient samples, GAS2L1P2 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
